Interleukin-6 as a Potential Biomarker of COVID-19 Progression
Médecine et Maladies Infectieuses, DOI: 10.1016/j.medmal.2020.04.002
Posted: 30 Mar 2020 Last revised: 7 Apr 2020
Date Written: March 18, 2020
Abstract
The rapid transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has resulted in the pandemic of Coronavirus Disease 2019 (COVID-19), affecting over 372.757 people worldwide. An increasing proportion of cases manifest as severe disease, characterised by respiratory disfunction and multi-organ failure. Previous studies have suggested the mechanisms of cytokine storm as a cause for progression and have measured associations between IL-6 levels and COVID-19 fatality. In this meta-analysis, we aimed to perform an evidence-based investigation on the role of IL-6 measurement to predict disease progression. Our results indicate that IL-6 may be important in identifying disease progression among COVID-19 infected patients.
Note: Funding: None.
Conflict of Interest: None to declare.
Keywords: SARS-CoV-2, COVID-19, Novel Coronavirus, IL-6, prognosis
Suggested Citation: Suggested Citation